Rakuten Securities Inc. Has $312,000 Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Rakuten Securities Inc. raised its stake in Moderna, Inc. (NASDAQ:MRNA) by 696.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,499 shares of the company’s stock after acquiring an additional 6,558 shares during the period. Rakuten Securities Inc.’s holdings in Moderna were worth $312,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the business. Janney Montgomery Scott LLC increased its holdings in Moderna by 6.3% in the 3rd quarter. Janney Montgomery Scott LLC now owns 12,767 shares of the company’s stock worth $853,000 after purchasing an additional 756 shares in the last quarter. Principal Financial Group Inc. increased its holdings in Moderna by 4.2% in the 3rd quarter. Principal Financial Group Inc. now owns 379,451 shares of the company’s stock worth $25,359,000 after purchasing an additional 15,218 shares in the last quarter. Apollon Wealth Management LLC increased its holdings in Moderna by 23.5% in the 3rd quarter. Apollon Wealth Management LLC now owns 5,064 shares of the company’s stock worth $338,000 after purchasing an additional 962 shares in the last quarter. Entropy Technologies LP acquired a new position in Moderna in the 3rd quarter worth about $778,000. Finally, GSA Capital Partners LLP acquired a new position in Moderna in the 3rd quarter worth about $377,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Analyst Ratings Changes

MRNA has been the topic of a number of analyst reports. Evercore ISI set a $50.00 price target on Moderna in a research report on Friday, February 14th. Piper Sandler reiterated an “overweight” rating and issued a $69.00 price target (down previously from $115.00) on shares of Moderna in a research report on Monday, November 18th. Barclays lowered Moderna from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $111.00 to $45.00 in a research report on Tuesday, February 18th. Wolfe Research began coverage on Moderna in a research report on Friday, November 15th. They set an “underperform” rating and a $40.00 target price on the stock. Finally, Hsbc Global Res upgraded Moderna from a “hold” rating to a “strong-buy” rating in a report on Monday, November 18th. Four equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $60.63.

Moderna Price Performance

NASDAQ:MRNA opened at $33.76 on Wednesday. The firm has a 50 day simple moving average of $36.38 and a 200-day simple moving average of $48.11. The firm has a market cap of $13.03 billion, a PE ratio of -3.64 and a beta of 1.86. Moderna, Inc. has a 1-year low of $29.25 and a 1-year high of $170.47.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.